|Mr. Ahmad Ali Mortazavi||CEO & Director||135.89k||N/A||1971|
|Dr. Karl Keegan BSc, MPhil, Ph.D., MSc||Chief Financial Officer||N/A||N/A||1967|
|Mr. Jonny Wray Ph.D.||Chief Technology Officer||N/A||N/A||N/A|
|Mr. Alan Whitmore B.Sc., Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Sarah Clare||Director of Fin. & Compliance||N/A||N/A||N/A|
|Ms. Stephanie Maley CIPD||Chief People Officer||N/A||N/A||N/A|
|Mr. Colin Stubberfield Ph.D.||Chief Research Officer||N/A||N/A||N/A|
|Dr. Laura Roca-Alonso Ph.D.||Chief Bus. Officer||N/A||N/A||N/A|
|Adam Sardar||Head of Data Science||N/A||N/A||N/A|
|Ms. Alison Gallafent||Head of Intellectual Property||N/A||N/A||N/A|
e-Therapeutics plc operates as a drug discovery company in the United Kingdom. The company's Network-Driven Drug Discovery platform perform in silico phenotypic screens to generate sets of small molecules that are enriched in active compounds ensuring high in vitro hit rates in complex phenotypic screens; and Genome-Associated Interaction Networks platform to analyze genome-wide association study data, which identifies disease variants at the genome level to identify potential intervention strategies, therapies, and diagnostics, as well as developing RNAi platform to modulate any gene to harness novel targets identified computationally. It also develops search engine technology. The company was founded in 2001 and is based in Long Hanborough, the United Kingdom.
e-Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.